Why has BIEL been rising? |
 |
 |
| By Vinny Cassano |
| Wednesday, 10 March 2010 03:00 |
 Shares of BioElectronics enjoyed a nice jump in price this week based on the release of an interview with CEO Andy Whelan
on SmallCapVoice.com.In part one, the CEO touched on some very significant subjects regarding the company and while CEOs are always supposed to sound optimistic, Mr. Whelan made it clear that big things are on the horizon for BioElectronics; even going so far as to state that the company is on the verge of becoming a "very significant" one. Of immediate interest, Mr. Whelan was confident that BIEL would become a fully reporting company in a matter of weeks when the 2009 audit is complete, a significant stepping stone for the company to move to the OTCBB - although he didn't rule out the possibility of an eventual move to the big boards, but one thing at a time. Nothing new was released regarding the status of the 510k and re-classification issues with the FDA - it's a waiting game as the FDA becomes "educated" on the products - but the CEO was extremely confident that over the short to mid term, both the ActiPatch and Allay products would be approved for OTC in the United States. Maybe more significant to the stock's price action is the fact that many of the brokers that were not allowing investors to purchase shares of BIEL are now starting to allow the transactions. Mr. Whalen mentioned Schwab, but I know that there were others not allowing BIEL orders as well. The relaxing of the restrictions is sure to help the BIEL stock price - there were quite a few investors who were standing on the sidelines waiting to get (back) in or add to their positions. Whelan interview was highly encouraging and confirms what many investors in BIEL have believed for some time - that the company could be on the verge of making a big impact in the global pain & swelling market. By no means is BioElectronics in the clear - hurdles still remain, but those able to buy in at the three cent level will reap significant rewards down the road, in my opinion. Disclosure: long BIEL BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 19 minutes ago
Focus on Perifosine May Shift For AEterna Zenatis Investors: Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) is an oncol... http://t.co/2ZZQbrSG
about 2 hours ago
NHS education reforms 'lack detail' http://t.co/YiUKVEsS
about 2 hours ago
Molecular 'on-off' switch for Parkinson's disease discovered http://t.co/wZ1N0xhq
about 2 hours ago
Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent http://t.co/CnJ8fKok
about 2 hours ago
Roche's dalcetrapib failure fuels HDL debate, but CETP not done yet http://t.co/8H9JRnp9
about 2 hours ago
Modest Gains Vanish As Stocks Reverse Lower http://t.co/AXlpfiAP
about 2 hours ago
Reading: One More Reason the Market's Pullback is Not Over http://t.co/iSZ0oYUq
about 9 hours ago
Novo’s Insulin Pill Quest is Holy Grail for Novo: Health http://t.co/1NixK9Mx
Free Phone Trade Alerts
